A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM

Type II Diabetes Mellitus Clinical Trial

Official title:

A Double-blind, Placebo-controlled, Randomised, Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KBP-089 in Patients With Type II Diabetes

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03907202
• Other study ID #: KBP089/CD/002
• Status: Terminated
• Phase: Phase 1
• Start date: April 17, 2018
• Est. completion date: December 3, 2019

Study information

• Verified date: September 2020
• Source: KeyBioscience AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

KeyBioscience is developing KBP-089, a dual activator of both the amylin and calcitonin receptors, for the treatment of type II diabetes mellitus, using a subcutaneous injectable mode of administration.

This is a double-blind, placebo-controlled, randomised, multiple-ascending dose phase I trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of KBP-089 in patients with type 2 diabetes, who are on stable therapy with metformin.

Subjects will receive daily subcutaneous injections in the abdomen over a period of 28 days. The planned maximum doses of KBP-089 to be investigated in the trial are 20 µg in cohort 1, 60 µg in cohort 2, and 150 µg in cohort 3. For cohort 1, the dose is planned to be escalated every 7 ±1 days, and for cohort 2 and cohort 3, every 3 days. Doses may be modified according to individual tolerability, but the dose regimen will not exceed 28 days.

The IMP is administered by daily subcutaneous injections taken in the morning before breakfast.

The trial is performed in Germany and at least 36 patients will be enrolled in the trial. The trial will be randomised 1:1:1 between maximum doses of KBP-089 of 20 µg, 60 µg, 150 µg and placebo. Within each of the three cohorts, 12 patients will be randomised 3:1 to KBP-089 and placebo.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 25
• Est. completion date: December 3, 2019
• Est. primary completion date: December 3, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedures that would not have been performed during normal management of the patient).

• Male or female patient with T2DM.

• Age between 18 and 64 years, both inclusive.

• Body Mass Index (BMI) >= 25.0 kg/m^2.

• HbA1c >= 7 and <=9.5%.

• Stable therapy with metformin ± treatment with a second oral anti-diabetes drug (OAD) belonging to the class of dipeptidyl-peptidase 4 (DPP-4) inhibitors or sulfonylureas for at least 2 months prior to inclusion into the trial or not treated with glucose-lowering medications. Patients who are receiving stable treatment with a second OAD will be asked to discontinue the DPP-4 inhibitor or a sulfonylurea for at least 14 days prior the Initial Inpatient Dosing Visit.

• Considered generally healthy (apart from T2DM) upon completion of medical history, physical examination, vital signs, ECG and analysis of laboratory safety variables, as judged by the Investigator.

Exclusion Criteria:

• Known or suspected hypersensitivity or allergy to paracetamol or related products.

• Prior treatment with a dual amylin and calcitonin receptor agonist (DACRA) or salmon calcitonin.

• Receipt of any medicinal product in clinical development within 30 days or 5 half-lives of the medicinal product (whichever is longer) before randomisation in this trial.

• History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.

• Any history or presence of clinically relevant cardiovascular, pulmonary, respiratory, gastrointestinal, hepatic, renal, metabolic, endocrinological (with the exception of conditions associated with diabetes mellitus), haematological, dermatological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynaecologic (if female), or infectious disease, or signs of acute illness as judged by the Investigator.

• Medically unable or unwilling to discontinue current anti-diabetic therapy with DPP-4 inhibitor or sulfonylurea for at least 14 days prior to admission to the research facility (Day -2) and remain off medication until the follow-up visit. Patients taking metformin therapy at entry will continue their metformin at the usual individual dose throughout the trial.

• Have had a significant change in weight, defined as a gain or loss of at least 5% body weight in the 3 months prior to screening.

• A positive result in the alcohol and/or urine drug screen at the screening visit.

• Positive to the screening test for Hepatitis Bs antigen (HBsAg) or Hepatitis C antibodies and/or a positive result to the test for human immunodeficiency virus (HIV)-1/2 antibodies or HIV-1 antigen.

• Have had a blood transfusion or severe blood loss within the past 6 months or have known hemoglobinopathy, hemolytic anemia, sickle cell anemia, or have a hemoglobin value <11 g/dL (males) or <10 g/dL (females), or any other condition known to interfere with HbA1c methodology.

• Blood donation or blood loss of more than 500 mL within the last 3 months or any blood donation within the last month prior to screening.

• Females of childbearing potential.

• Males with pregnant partners.

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Type II Diabetes Mellitus

Intervention

Drug:
• Daily injection of KBP/placebo for up to 28 days
Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.

Locations

Country	Name	City	State
Germany	Profil Institut für Stoffwechselforschung GmbH	Neuss

Sponsors (4)

Lead Sponsor	Collaborator
KeyBioscience AG	Eli Lilly and Company, Nordic Bioscience A/S, Profil Institut für Stoffwechselforschung GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment Emergent Adverse Events (TEAEs).	All TEAEs will be coded using MedDRA and summarized by treatment and dose.	Day -1 to day 28
Primary	Vital sign - Blood Pressure.	Diastolic and systolic blood pressure (mmHg) are measured after at least 5 min rest in a supine position.; Vital signs will be summarised by descriptive statistics by treatment, dose and timepoint.	Day -1 to day 28
Primary	Vital sign - Pulse (beats per min).	measured after at least 5 min rest in a supine position. Vital signs will be summarised by descriptive statistics by treatment, dose and timepoint.	Day -1 to day 28
Primary	Vital sign - Body Temperature.	Body temperature, tympanic (in Celcius). Vital signs will be summarised by descriptive statistics by treatment, dose and timepoint.	Day -1 to day 28
Primary	Vital sign - Respiratory frequency.	Respiratory frequency measured as breaths per min. Vital signs will be summarised by descriptive statistics by treatment, dose and timepoint.	Day -1 to day 28
Primary	Electrocardiogram (ECG) - PQ interval.	PQ interval (in msec) and any abnormality will be recorded and described in the CRF including the Investigator's assessment of clinical significance ('abnormal, not clinically significant' or 'abnormal, clinically significant').	Day -1 to day 28
Primary	Electrocardiogram (ECG) - QRS complex.	QRS interval (in msec) and any abnormality will be recorded and described in the CRF including the Investigator's assessment of clinical significance ('abnormal, not clinically significant' or 'abnormal, clinically significant').	Day -1 to day 28
Primary	Electrocardiogram (ECG) - QT interval.	QT interval (in msec) and any abnormality will be recorded and described in the CRF including the Investigator's assessment of clinical significance ('abnormal, not clinically significant' or 'abnormal, clinically significant').	Day -1 to day 28
Primary	Safety laboratory parameter - lipids.	Standard Lipid assessments will be summarized by treatment (including dose) using descriptive statistics (number, mean, standard deviation, minimum, median and maximum).; (Lipid parameters measured: Total cholesterol, High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Triglycerides).	Day -1 to day 28
Primary	Safety laboratory parameter - haematology.	Standard Biochemistry assessments will be summarized by treatment (including dose) using descriptive statistics (number, mean, standard deviation, minimum, median and maximum).; (Haematology parameters measured: Haematocrit, Haemoglobin, Erythrocytes, Mean corpuscular volume (MCV), Mean corpuscular haemoglobin (MCH), Mean corpuscular haemoglobin concentration (MCHC), Thrombocytes (platelets), Leucocytes, Neutrophile granulocytes (total count and relative), Lymphocytes (total count and relative), Monocytes (total count and relative), Eosinophile granulocytes (total count and relative), Basophile granulocytes (total count and relative))	Day -1 to day 28
Primary	Safety laboratory parameter - coagulation.	Standard coagulation assessments will be summarized by treatment (including dose) using descriptive statistics (number, mean, standard deviation, minimum, median and maximum).; (coagulation parameters measured: International normalised ratio (INR), Activated partial thromboplastin time (APTT)	Day -1 to day 28
Primary	Safety laboratory parameter - urinalysis.	Standard Biochemistry assessments will be summarized by treatment (including dose) using descriptive statistics (number, mean, standard deviation, minimum, median and maximum).; (Urinalysis parameters measured: Protein, Glucose, Erythrocytes, Leucocytes, pH, Ketones)	Day -1 to day 28
Secondary	Pharmacokinetic Evaluation - KBP-089 Area Under Curve.	PK parameter (AUC 0-24) will be derived by non-compartmental analysis of the plasma concentration data for KBP-089	Day -1 to day 28
Secondary	Pharmacokinetic Evaluation - KBP-089 Cmax.	PK parameter (Cmax) will be derived by non-compartmental analysis of the plasma concentration data for KBP-089	Day -1 to day 28
Secondary	Gastric emptying - Paracetamol Cmax.	Gastric emptying is measured using paracetamol Cmax at baseline (Day -1), Day 1, and Day 28 for Cohorts 1 and 2 only	Day -1 to day 28
Secondary	Gastric emptying - Paracetamol Tmax.	Gastric emptying is measured using paracetamol Tmax at baseline (Day -1), Day 1, and Day 28 for Cohorts 1 and 2 only	Day -1 to day 28
Secondary	Gastric emptying - Paracetamol Area Under Curve (AUC).	Gastric emptying is measured using paracetamol AUC at baseline (Day -1), Day 1, and Day 28 for Cohorts 1 and 2 only	Day -1 to day 28
Secondary	Fasting and postprandial glucose concentration.	Fasting and postprandial glucose following OGTT at baseline (Days -1) and Day 28	Day -1 to day 28
Secondary	Fasting and postprandial insulin concentration.	Insulin following OGTT at baseline (Days -1) and Day 28	Day -1 to day 28
Secondary	Fasting and postprandial C-peptide concentration.	Fasting and postprandial C-peptide following OGTT at baseline (Days -1) and Day 28	Day -1 to day 28
Secondary	Fasting and postprandial glucagon concentration.	Fasting and postprandial glucagon following OGTT at baseline (Days -1) and Day 28	Day -1 to day 28
Secondary	Body weight.	Body weight at Day -1 (baseline) and Day 28 (in kg)	Day -1 to day 28
Secondary	N-(1-deoxy)-fructosyl-haemoglobin (HbA1c).	HbA1c at Day -1 (baseline) and Day 28 (in mmol/mol)	Day -1 to day 28
Secondary	Fridericia's corrected QT interval (QTcF).	Fridericia's corrected QT interval (QTcF) at Day 1 and Day 27 (in msec)	Day 1 to day 27